Mechanisms of Termination of Atrial Fibrillation by Class I Antiarrhythmic Drugs: Evidence from Clinical, Experimental, and Mathematical Modeling Studies

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 10 SUPPL., 2003, Pages

  Nattel, Stanley ^a,b,d   Kneller, James ^a,b   Zou, Renqiang ^a   Leon, L Joshua ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Atrial fibrillation; Class I antiarrhythmic drug

Indexed keywords

ANTIARRHYTHMIC AGENT; CIBENZOLINE; ENCAINIDE; FLECAINIDE; PILSICAINIDE; PROPAFENONE; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; HEART; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HUMAN; MATHEMATICAL MODEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REENTRY ARRHYTHMIA; SINUS RHYTHM; STATISTICAL MODEL;

EID: 0242440066     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540.8167.90302.x     Document Type: Conference Paper

References (33)

1. Parkinson J, Campbell M: The quinidine treatment of auricular fibrillation. Q J Med 1929;22:281-303.
2. Lewis T, Drury AN, Wedd AM, Iliescu CC: Observations upon the action of certain drugs upon fibrillation of the auricles. Heart 1922;9:207-267.
3. Yang T, Roden DM: Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93:407-411.
4. Moe GK, Rheinboldt WC, Abildskov JA: A computer model of atrial fibrillation. Am Heart J 1964;67:200-220.
5. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-226.
6. Allessie MA, Bonke FI, Schopman FJ: Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977:41:9-18.
7. Kappenberger LJ, Fromer MA, Shenasa M, Gloor HO: Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 1985;8:321-326.
8. Goy JJ, Maendly R, Grbic M, Finci L, Sigwart U: Cardioversion with flecainide in patients with atrial fibrillation of recent onset. Eur J Clin Pharmacol 1985;27:737-738.
9. Pritchett EL, DaTorre SD, Platt ML, McCarville SE, Hougham AJ: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response studies. The Flecainide Supraventricular Tachycardia Study Group. J Am Coll Cardiol 1991;17:297-303.
10. Suttorp MJ, Kingma JH, Jessurun ER, Lie-A-Huen L, van Hemel NM, Lie KI: The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-1727.
11. Rinkenberger RL, Naccarelli GV, Miles WM, Markel ML, Dougherty AH, Prystowsky EN, Heger JJ, Zipes DP: Encainide for atrial fibrillation associated with Wolff-Parkinson-White syndrome. Am J Cardiol 1988;62:26L-30L.
12. Okishige K, Nishizaki M, Azegami K, Igawa M, Yamawaki N, Aonuma K: Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: A placebo-controlled, multicenter study. Am Heart J 2000;140:437-444.
13. Follmer CH, Cullinan CA, Colatsky TJ: Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: Evidence for open channel block and unblock. Cardiovasc Res 1992;26:1121-1130.
14. Duan D, Fermini B. Nattel S: Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
15. Yamashita T, Murakawa Y, Sezaki K, Hayami N, Inoue M, Fukui E, Omata M: Uniqueness of pilsicainide in class Ic antiarrhythmics. Jpn Heart J 1998;39:389-397.
16. Biffi M, Boriani G, Bronzetti G, Capucci A, Branzi A, Magnani B: Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination. Heart 1999;82:176-182.
17. Brugada J, Gursoy S, Brugada P, Atie J, Guiraudon G, Andries E: Cibenzoline transforms random re-entry into ordered re-entry in the atria. Eur Heart J 1993;14:267-272.
18. Asano Y, Saito J, Matsumoto K, Kaneko K, Yamamoto T, Uchida M: On the mechanism of termination and perpetuation of atrial fibrillation. Am J Cardiol 1992;69:1033-1038.
19. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988;62:395-410.
20. Wang Z, Pagé P, Nattel S: Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res 1992;71:271-287.
21. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S: Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. The importance of use-dependent effects on refractoriness. Circulation 1993;88:1030-1044.
22. Kirchhof C, Wijffels M, Brugada J, Planellas J, Allessie M: Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol 1991;17:116-124.
23. David D, Lang RM, Neumann A, Borow KM, Akselrod S, Mor-Avi V: Parasympathetically modulated antiarrhythmic action of lidocaine in atrial fibrillation. Am Heart J 1990;119:1061-1068.
24. Kanki H, Mitamura H, Takatsuki S, Sueyoshi K, Shinagawa K, Sato T, Ogawa S: Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. Cardiovasc Drugs Ther 1998;12:475-482.
25. Shinagawa K, Mitamura H, Takeshita A, Sato T, Kanki H, Takatsuki S, Ogawa S: Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: Direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol 2000;35:246-253.
26. Wijffels MC, Dorland R, Mast F, Allessie MA: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: Effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation 2000;102:260-267.
27. Kawase A, Ikeda T, Nakazawa K, Ashihara T, Namba T, Kubota T, Sugi K, Hirai H: Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. Circulation 2003;107:905-910.
28. Jalife J, Bernefeld O, Mansour M: Mother rotors and fibrillatory conduction: A mechanism of atrial fibrillation. Cardiovasc Res 2002;54:204-216.
29. Schuessler RB, Grayson TM, Bromberg BI, Cox JL, Boineau JP: Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 1992;71:1254-1267.
30. Ramirez RJ, Nattel S, Courtemanche M: Mathematical analysis of canine atrial action potentials: Rate, regional factors, and electrical remodeling. Am J Physiol 2000;279:H1767-H1785.
31. Kneller J, Zou R, Vigmond EJ, Wang Z, Leon LJ, Nattel S: Cholinergic atrial fibrillation in a computer model of two-dimensional sheet of canine atrial cells with realistic ionic properties. Circ Res 2002;90:E73-E87.
32. Chen J, Mandapati R, Berenfeld O, Skanes AC, Gray RA, Jalife J: Dynamics of wavelets and their role in atrial fibrillation in the isolated sheep Heart. Cardiovasc Res 2000;48:220-232.
33. Kneller J, Leon J, Nattel S: How do class 1 antiarrhythmic drugs terminate atrial fibrillation? A quantitative analysis based on a realistic ionic model. (Abstract) Circulation 2001;104(Suppl II):II-5.